As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.

As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."

How Did The Report Conclude?

The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.

What Did The Results Reveal?

The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.

Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.

Is The LGBTQ+ Prone To Mental Health Crisis?

As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.

A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.

What Do These Findings Mean?

TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."

Nearly 90,000 bottles of children's ibuprofen have been recalled nationwide after complaints were made that the medication could contain a foreign substance. The federal health officials complained about the foreign substance due to which Strides Pharma Inc., headquartered in India recalled about 89,592 bottles of Children's Ibuprofen Oral Suspension, noted the US Food and Drug Administration.

The recall happened after reports of a gel-like mass and black particles were found in the products.

FDA Issues Class II Recall Against Children's Ibuprofen

The FDA has issued a Class II recall, which means the use of the affection medication could cause temporary or medically reversible health problems. It also translates to serious harm being considered remote.

FDA has three categories for recall, Class I, Class II, and Class II. Class I recalls usually mean high risk. This could mean that defective products could cause serious health problems or death. Class II is for moderate risk, which has been issued for children's ibuprofen. Class III is for products with low risk. This is for products that are unlikely to cause any adverse health consequence, but they violate FDA labeling or manufacturing regulations.

Read: E. Coli Outbreak Linked To Cheddar Cheese, 7 People In 3 States Affected

India-based Pharmaceutical Company Recalls Nearly 90,000 Bottles Of Ibuprofen

The India headquartered company Strides Pharma was manufacturing the product for Taro Pharmaceuticals USA Inc. and the products were distributed across the United States.

The recalled medication is for the 100-milligram per 5-milliliter oral suspension sold in 4-fluid-ounce bottles. The affected lot numbers are 7261973A and 7261974A, with an expiration date of Jan. 31, 2027. The recall number is D-0390-2026.

Health officials have advised consumers who have the recalled ibuprofen to stop using it. The FDA however has not yet received reports of serious adverse health effects related to the recalls.

Previous Cases Where Indian Drugmakers Distributing To US Recalled Their Products

Certain products were recalled from the US market due to manufacturing relayed issues. These products were by Indian drugmakers Sun Pharmaceutical Industries and Cipla. In an Enforcement Report by the FDA, it noted that the US-based arm of Mumbai-headquartered Sun Pharma has recalled more than 26,000 bottles of generic medicine used to treat dandruff and skin conditions that cause inflammation and itching. Sun Pharma, based in Princeton, New Jersey, recalled 24,624 bottles of Fluocinolone Acetonide Topical Solution after the product failed to meet impurity and degradation standards. The company also initiated Class III recall in US on December 30, 2025.

Cipla recalled over 15,000 syringes from the US market. Headquartered in Warren, New Jersey, the company recalled 15,221 pre-filled syringes of Lanreotide Injection due to the presence of particulate matter. Cipla also initiated a recall of Class II on January 2 of this year.

UK health officials have identified seven more cases of meningitis, as part of the latest outbreak in Kent, taking the total number of cases to 27. They expect the numbers to rise in the coming days.

The UK Health Security Agency noted that it has expanded the Meningitis B vaccine regimen to everyone who has been offered preventative antibiotic treatment as part of this outbreak.

“15 laboratory cases are confirmed and 12 notifications remain under investigation, bringing the total to 27,” the UKHSA said in a statement.

“Currently, cases have been confirmed in students at 4 schools in Kent, as well as one student at a higher education institution in London (who is confirmed to be directly linked to the outbreak),” it added.

Two students -- a 21-year-old student at the University of Kent and a teenage student at a school in the town of Faversham have died in the outbreak.

A 9-month-old baby from Folkestone is reportedly battling for life in the intensive care unit.

Meanwhile, another university in the city confirmed a case of meningitis. The student at Canterbury Christ Church is believed to be a man who was at the nightclub and part of the initial cluster of 20 known cases, who visited Club Chemistry in Canterbury between March 5 and 7.

"We are not in the position yet to say definitively that it's been contained," Dr Anjan Ghosh, Director of Public Health at Kent County Council, told BBC Radio, adding that secondary transmissions needed to be ruled out.

Calling the outbreak “unprecedented”, Health Minister Wes Streeting said: “The number of suspected cases was expected to increase ‌in ⁠the coming days because the disease had a seven- to 10-day incubation period”, Reuters reported.

In a typical year, Britain sees about 350 cases, roughly one per day, according to government estimates.

In addition to the approximately 5,000 students who were initially contacted, vaccination will now be extended to everyone who has been offered preventative antibiotic treatment as part of this outbreak, the UKHSA said.

Why The Cases Are Rising

While it remains unclear why the outbreak has been so large, “the large number of cases all originating from what seems to be a single event” is particularly striking, Prof Robin May, the chief scientific officer at the UKHSA, told the BBC Breakfast.

May said that "there might be something about the kind of behaviors that individual people are doing." Another probable reason "is that the bacteria may have evolved to be better at transmitting".

Both the UKHSA and the European Centre for Disease Prevention and Control maintain that the risk of invasive meningococcal disease to the general population in Europe is "very low".

Also read: From Vaping to Worm Attack: 5 Unimaginable Ways to Contract Meningitis

Can The Outbreak Be Prevented?

The UKHSA noted that the key intervention to protect people and halt the spread remains for people to come forward for antibiotic treatment -- effective in preventing contraction and spreading in 90 percent of cases.

In addition, a targeted MenB vaccination program is also being introduced for longer-term protection.

“By extending the vaccination program to everyone who has been offered preventative antibiotics, we are taking an important additional step to protect those most likely to have been exposed. The message is simple: if you have had the antibiotic, you are also eligible for the vaccination,” said Professor Susan Hopkins, Chief Executive of the UKHSA.

However, Trish Mannes, UKHSA Regional Deputy Director for the South East, noted that even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.

The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhoea
• joint and muscle pain
• seizures.

The widespread use of Azithromycin to treat hospitalized patients during the COVID-19 pandemic increased the risk of antimicrobial resistance -- a major global health problem, according to a new study, published in the journal Nature Microbiology.

Scientists at the University of California-San Francisco (UCSF) noted that using azithromycin inappropriately for even a single day can trigger antibiotic resistance in the respiratory tract.

While azithromycin is effective against bacterial infections that cause strep throat, pneumonia, and sexually transmitted diseases, it does not work against viruses.

"We've known for years that antibiotics don't treat viral infections, but these results were striking," said Chaz Langelier, from UCSF.

"That we could see resistance genes turning on in the respiratory tract within a day tells us the consequences of unnecessary antibiotic use aren't theoretical or long-term. They're immediate, measurable, and biologically real," Langelier added.

The study analyzed nasal swabs of 1,164 adults hospitalized for COVID-19 to examine the changes that occurred in the microbiome of hospitalized patients who were treated for COVID.

Compared to people who received no antibiotics, patients administered azithromycin reported changes that persisted for more than a week. These include:

• Changes in the mix of microbes in the upper airway
• Decrease in harmless bacteria,
• Surge in potentially harmful bacteria such as Staphylococcus and Klebsiella.

Rising Global Antimicrobial Resistance

Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them.

It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections.

As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.

In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to the CDC's 2019 Antibiotic Resistance (AR) Threats Report.

The WHO, in a 2025 report, noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments.

Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent.

US Early Death Toll During COVID Much Higher

About 16 per cent of COVID-19 deaths went uncounted early in the pandemic in the US, according to a separate study, published by the journal Science Advances.

While about 840,000 COVID deaths were reported on death certificates in 2020 and 2021, the researchers using artificial intelligence (AI) decoded that as many as 155,000 unrecognised additional deaths likely occurred in that time outside of hospitals.